Research Article
Modulation of Molecular Biomarker Expression in Response to Chemotherapy in Invasive Ductal Carcinoma
Table 1
Clinical and pathological characteristics of the patients.
| Characteristics | N | % |
| Overall series of patients | 30 | 100 | Mean age = 45 (range: 31–56 years) | | | Age < 45 | 16 | 53.33 | Age ≥ 45 | 14 | 46.66 | Menopausal status | | | Pre | 10 | 33.33 | Post | 20 | 66.66 | Histological diagnosis | | | Invasive ductal carcinoma | 26 | 86.66 | Invasive lobular carcinoma | 2 | 6.66 | Other subtypes | 2 | 6.66 | Tumor size | | | ≤2 cm | 12 | 40 | >2 cm | 18 | 60 | Stage | | | I | 11 | 36.33 | II and III | 19 | 63.66 | Lymph node involvement | | | Negative | 20 | 66.66 | Positive | 10 | 33.33 | Nuclear grade | | | I | 4 | 13.33 | II | 16 | 53.33 | III | 10 | 33.33 | Receptor status | | | | 16 | 53.33 |
| 14
| 46.66
| Immunohistochemical profile | | | Luminal A/B Basal-like | 16 14 | 53.33 46.66 | Mean follow-up = 3 years | | |
|
|
N: number of subjects; includes mucinous and papillary carcinomas; ER: estrogen receptor; luminal A: HER +, ER +/PR +; luminal B: HER2 −/ER +/PR +; basal-like: HER2 −, ER −/PR −. |